Foundation / Corporation
Susan G. Komen
09/25/19 1:00 PM EST
Grants to USA, Canada, and International early-career researchers for long-term studies to address metastatic breast cancer treatments and early detection. Applicants must submit a letter of interest prior to applying. Proposals must address liquid biopsy detection or treatment methods. Funding is intended to provide researchers with the preparation required to compete for independent funding as an established and successful breast cancer researcher. Proposals must focus on either refining treatment of metastatic breast cancer or early detection of metastatic breast cancer.
For the current funding cycle the area of interest is redefining metastatic breast cancer through liquid biopsy. The goal of this focus area is to support outstanding research seeking to use liquid biopsy techniques to improve treatment, detection, and understanding of metastatic breast cancer which will lead to a reduction in breast cancer deaths by 2026. A liquid biopsy is defined as the collection and analysis of a sample of blood to detect cancer cells or pieces of DNA from cancer cells that are circulating in the blood.
1. Refining treatment of metastatic breast cancer: The goal of this focus area is to support studies that leverage liquid biopsy approaches to improve the treatment of metastatic breast cancer. Appropriate studies for this mechanism include, but are not limited to:
- Using liquid biopsies to track the response of metastatic breast cancer to therapy, including host immune response to immunotherapy approaches, genomic responses, or resistance mechanisms.
- Using liquid biopsies to identify and validate circulating biomarkers that will predict response to therapy and optimize therapeutic interventions for metastatic breast cancer.
- Combining liquid biopsy techniques and data science methods to gain new insights into the biology or treatment of metastatic breast cancer.
2. Early detection of metastatic breast cancer: The goal of this focus area is to support studies that will use liquid biopsies to develop new approaches to detect new or recurrent metastatic breast cancer as early as possible, before standard symptoms may be detectable. Appropriate studies for this mechanism include, but are not limited to:
- Development and testing of novel liquid biopsy technologies and methods for early detection of metastatic breast cancer.
- Identification and validation of liquid biopsy diagnostic or prognostic circulating biomarkers, including micro-metastases, for the earliest possible detection of metastatic breast cancer.
- Using liquid biopsy techniques and analyses to predict metastatic breast cancer recurrence, including identification of tumor dormancy or treatment-resistant cancer cells.
Applications that fit these focus areas and include studies that address metastatic breast cancer disparities, or leverage data science to better understand and treat metastatic breast cancer are highly encouraged.For these purposes, metastatic breast cancer disparities research is defined as research investigating the biologic, behavioral, social and systems contributors to late-stage (metastatic) breast cancer in population groups affected by breast cancer disparities. This may include the identification, validation and testing of biological and/or socioeconomic factors that contribute to breast cancer disparities in metastatic breast cancer. This may also include identification of health services and public health interventions that address the causes of disparities in care and outcomes across population groups in metastatic breast cancer. Data science includes artificial intelligence and other analytical methods applied to data aggregated from multiple sources (Electronic Health Records, other clinical data, administrative databases, large data repositories, genomics and other -omics data, etc.).
For budgetary guidelines, see:
GrantWatch ID#: 181654
Applicants/PIs may request funding of up to $150,000 per year (combined direct and indirect costs) for up to three years ($450,000).
Grants are up to three years.
Before starting your grant application, please review the funding source's website listed below for updates/changes/addendums/conferences/LOIs.
To start a LOI, go to:
For technical assistance with proposalCentral:
Toll-free within the US and Canada: 1‐800‐875‐2562
Direct programmatic inquiries to: http://www.komen.org/researchhelpdesk
For assistance in identifying trained advocates: email@example.com
Susan G. Komen
5005 LBJ Freeway, Suite 250
Dallas, Texas 75244
USA: Alabama; Alaska; Arizona; Arkansas; California; Colorado; Connecticut; Delaware; Florida; Georgia; Hawaii; Idaho; Illinois; Indiana; Iowa; Kansas; Kentucky; Louisiana; Maine; Maryland; Massachusetts; Michigan; Minnesota; Mississippi; Missouri; Montana; Nebraska; Nevada; New Hampshire; New Jersey; New Mexico; New York City; New York; North Carolina; North Dakota; Ohio; Oklahoma; Oregon; Pennsylvania; Rhode Island; South Carolina; South Dakota; Tennessee; Texas; Utah; Vermont; Virginia; Washington, DC; Washington; West Virginia; Wisconsin; Wyoming
USA Territories: American Samoa (USA) Guam (USA) Puerto Rico (USA) Virgin Islands (USA) Northern Mariana Islands (USA)
USA Compact Free Associations: The Federated States of Micronesia (USA) Marshall Islands (USA) Republic of Palau (USA)
Canada: Alberta British Columbia Manitoba New Brunswick Newfoundland and Labrador Northwest Territories Nova Scotia Nunavut Ontario Prince Edward Island Quebec Saskatchewan Yukon
International country outside of the USA, Israel and Canada.